Novartis Hong Kong general manager Dorine Leung and oncology head Sian Ng discuss the company’s restructuring, dividing the oncology business unit from the pharmaceutical division. In addition, they share their insights on what makes Hong Kong a destination for world-class clinical trials.
Novartis recently underwent a major restructuring with the goal of becoming a fully integrated company, most notably through the separation of the Oncology business unit from the Pharmaceuticals business unit under a broader ‘Innovative Medicines’ division. How does that fit and translate into the local Hong Kong context?
"One advantage of Hong Kong is the beauty of its small size, so it is possible for me to communicate directly with my team."
